Susan Wachter
Internal Medicine · Idaho Falls, IDNPI 1740450014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,370 of the $22,237 with a category attached, or 69.1%. Novartis accounts for 89.4% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $19,113 and has fallen 98.0% since, to $386 in 2025. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $80.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$20K
- Abbott$444
- Pfizer$393
- E.r. Squibb & Sons, L.L.C.$318
- Abiomed$188
- Johnson & Johnson$166
- plus $841 from 22 others
What the payments were for
- Speaking & faculty fees$15,37069%
- Travel & lodging$3,18714%
- Food & beverage$3,64416%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 119 | $19,886 |
| Abbott | 17 | $444 |
| Pfizer | 27 | $393 |
| E.r. Squibb & Sons, L.L.C. | 45 | $318 |
| Abiomed | 3 | $188 |
| Johnson & Johnson | 12 | $166 |
| Boston Scientific | 7 | $108 |
| Medtronic(2 entities) | 5 | $96 |
| Actelion Pharmaceuticals US, Inc. | 9 | $84 |
| Merck | 5 | $81 |
| Scpharmaceuticals Inc. | 3 | $54 |
| AstraZeneca | 3 | $47 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| GE HealthCare | 1 | $30 |
| Boehringer Ingelheim | 1 | $23 |
| Mannkind Corporation | 1 | $23 |
| Bayer | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Philips North America LLC | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Teleflex LLC | 1 | $14 |
| Impulse Dynamics (USA) Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,237 in reported general payments places this provider in the 95th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 277 | $249,061 |
| EliquisApixaban | 232 | $230,145 |
| FarxigaDapagliflozin Propanediol | 168 | $147,377 |
| XareltoRivaroxaban | 83 | $83,283 |
| BrilintaTicagrelor | 64 | $40,551 |
| DapagliflozinDapagliflozin Propanediol | 19 | $11,275 |
| Prasugrel Hcl | 35 | $8,992 |
| Potassium Chloride | 230 | $7,363 |
| Torsemide | 174 | $7,001 |
| Atorvastatin Calcium | 428 | $4,240 |
| Metoprolol Succinate | 244 | $2,613 |
| Carvedilol | 294 | $2,477 |
| Amiodarone Hcl | 129 | $2,125 |
| Furosemide | 286 | $1,352 |
| Losartan Potassium | 199 | $1,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $19,886 | $249,061277 claims |
| PfizerEliquis | $393 | $230,145232 claims |
| AstraZenecaFarxiga, Brilinta | $47 | $187,927232 claims |
| Johnson & JohnsonXarelto | $166 | $83,28383 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Idaho Falls
- Ahmed MahmoodIdaho Falls$21K
- Kevin PrierIdaho Falls$6K
- Brady CookIdaho Falls$6K
- Scott TaylorIdaho Falls$5K
- Johnathan LiljenquistIdaho Falls$525
- Leland KrantzIdaho Falls$447
- Alan AvondetIdaho Falls$411
- Margaret BakerIdaho Falls$403
- Allen SwansonIdaho Falls$303
- Sherwin D'souzaPocatello$543K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.